Navigation Links
SpectraScience Awarded Patent for Correcting Image Misalignment
Date:8/13/2008

SAN DIEGO, Aug. 13 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical devices company, today announced that it has been awarded a patent for correcting image misalignment between at least two images in a sequence of images due at least in part to tissue sample movement. The patent, U.S. Patent No. 7,406,215, is titled "Methods and systems for correcting image misalignment."

Jim Hitchin, SpectraScience's CEO, commented, "This is another key patent in our broad patent portfolio that furthers our commitment at SpectraScience to develop better, more reliable cancer screening technologies.

The patent is important to the Company's optical biopsy technology because, in screening for some forms of cancer, the optical response of the tissue is captured in a sequence of images that are characterized by analyzing the time-dependent response of the tissue as recorded in the sequence. During this type of screening, the tissue may move while images are being taken, resulting in a spatial shift within the image frame field. Being able to correct for this shift increases the effectiveness of the optical biopsy procedure. Tissue movement can be caused by the natural movement of the patient during the procedure, which can occur despite a patient's attempts to remain completely still. This patent provides for an accurate analysis of the sequence of images which would otherwise be misaligned due to movement of the tissue.

Hitchin added, Accurate imaging is critical to earlier and more effective identification of abnormal, pre-cancerous and/or cancerous tissue, and this invention provides methods of determining a correction for a misalignment in the imaging process that will make our screening devices more powerful to the physician and more important to the patient."

SpectraScience has filed for 60 patents worldwide on its WavSTAT(R) Optical Biopsy System and LUMA(R) Cervical Imaging System that are used to diagnose tissue to quickly determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are currently approved by the FDA for detecting pre-cancer and cancer in the colon and cervix, and an evaluation for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward- looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

Contact:

SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer

(858) 847-0200 x201

Hayden Communications

Investor Relations

Todd Pitcher

(858)-518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
6. SpectraScience Adds Industry Veteran to Executive Team
7. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
8. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
9. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
10. PartsSource Awarded US Patent for PartsFinder(TM) Application
11. Wrigleys Orbit(R), Extra(R) and Eclipse(R) Sugar-Free Chewing Gums Awarded American Dental Associations Seal of Acceptance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: